nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—KIT—muscle cancer	0.492	1	CbGaD
Regorafenib—UGT1A1—Etoposide—muscle cancer	0.0427	0.173	CbGbCtD
Regorafenib—ABCG2—Dactinomycin—muscle cancer	0.0416	0.169	CbGbCtD
Regorafenib—ABCG2—Vincristine—muscle cancer	0.0256	0.104	CbGbCtD
Regorafenib—ABCG2—Etoposide—muscle cancer	0.0235	0.0951	CbGbCtD
Regorafenib—ABCG2—Doxorubicin—muscle cancer	0.016	0.0649	CbGbCtD
Regorafenib—ABCG2—Methotrexate—muscle cancer	0.0155	0.0628	CbGbCtD
Regorafenib—ABCB1—Dactinomycin—muscle cancer	0.015	0.0608	CbGbCtD
Regorafenib—CYP2C8—Etoposide—muscle cancer	0.0125	0.0507	CbGbCtD
Regorafenib—CYP2B6—Doxorubicin—muscle cancer	0.0113	0.0456	CbGbCtD
Regorafenib—ABCB1—Vincristine—muscle cancer	0.00924	0.0374	CbGbCtD
Regorafenib—ABCB1—Etoposide—muscle cancer	0.00847	0.0343	CbGbCtD
Regorafenib—ABCB1—Doxorubicin—muscle cancer	0.00577	0.0234	CbGbCtD
Regorafenib—ABCB1—Methotrexate—muscle cancer	0.00559	0.0227	CbGbCtD
Regorafenib—CYP3A4—Vincristine—muscle cancer	0.00554	0.0224	CbGbCtD
Regorafenib—CYP3A4—Etoposide—muscle cancer	0.00507	0.0206	CbGbCtD
Regorafenib—CYP3A4—Doxorubicin—muscle cancer	0.00346	0.014	CbGbCtD
Regorafenib—Sorafenib—KIT—muscle cancer	0.00321	1	CrCbGaD
Regorafenib—KDR—hindlimb—muscle cancer	0.00261	0.0358	CbGeAlD
Regorafenib—KDR—appendage—muscle cancer	0.00224	0.0307	CbGeAlD
Regorafenib—FRK—renal system—muscle cancer	0.00157	0.0215	CbGeAlD
Regorafenib—DDR2—smooth muscle tissue—muscle cancer	0.00146	0.02	CbGeAlD
Regorafenib—NTRK1—testis—muscle cancer	0.00122	0.0168	CbGeAlD
Regorafenib—FLT4—embryo—muscle cancer	0.00113	0.0155	CbGeAlD
Regorafenib—DDR2—tendon—muscle cancer	0.0011	0.015	CbGeAlD
Regorafenib—DDR2—vagina—muscle cancer	0.00102	0.014	CbGeAlD
Regorafenib—FRK—testis—muscle cancer	0.00101	0.0139	CbGeAlD
Regorafenib—RET—embryo—muscle cancer	0.000997	0.0137	CbGeAlD
Regorafenib—FGFR2—embryo—muscle cancer	0.000948	0.013	CbGeAlD
Regorafenib—DDR2—head—muscle cancer	0.000939	0.0129	CbGeAlD
Regorafenib—Mucosal inflammation—Etoposide—muscle cancer	0.000915	0.0191	CcSEcCtD
Regorafenib—TEK—embryo—muscle cancer	0.000909	0.0125	CbGeAlD
Regorafenib—DDR2—testis—muscle cancer	0.000907	0.0124	CbGeAlD
Regorafenib—Hepatotoxicity—Dactinomycin—muscle cancer	0.000907	0.0189	CcSEcCtD
Regorafenib—MAPK11—head—muscle cancer	0.00089	0.0122	CbGeAlD
Regorafenib—FLT1—embryo—muscle cancer	0.000878	0.0121	CbGeAlD
Regorafenib—RAF1—embryo—muscle cancer	0.000873	0.012	CbGeAlD
Regorafenib—UGT1A9—renal system—muscle cancer	0.000867	0.0119	CbGeAlD
Regorafenib—MAPK11—testis—muscle cancer	0.00086	0.0118	CbGeAlD
Regorafenib—PDGFRA—embryo—muscle cancer	0.000823	0.0113	CbGeAlD
Regorafenib—Nail disorder—Etoposide—muscle cancer	0.000781	0.0163	CcSEcCtD
Regorafenib—BRAF—tendon—muscle cancer	0.000774	0.0106	CbGeAlD
Regorafenib—Hypocalcaemia—Dactinomycin—muscle cancer	0.000765	0.016	CcSEcCtD
Regorafenib—FGFR1—cardiac atrium—muscle cancer	0.000756	0.0104	CbGeAlD
Regorafenib—RET—renal system—muscle cancer	0.000755	0.0104	CbGeAlD
Regorafenib—BRAF—bone marrow—muscle cancer	0.00075	0.0103	CbGeAlD
Regorafenib—FGFR2—smooth muscle tissue—muscle cancer	0.000745	0.0102	CbGeAlD
Regorafenib—KDR—embryo—muscle cancer	0.000743	0.0102	CbGeAlD
Regorafenib—EPHX2—tendon—muscle cancer	0.00074	0.0102	CbGeAlD
Regorafenib—BRAF—vagina—muscle cancer	0.000719	0.00986	CbGeAlD
Regorafenib—FGFR2—renal system—muscle cancer	0.000717	0.00984	CbGeAlD
Regorafenib—TEK—smooth muscle tissue—muscle cancer	0.000714	0.0098	CbGeAlD
Regorafenib—ABL1—Epirubicin—Doxorubicin—muscle cancer	0.00071	0.333	CbGdCrCtD
Regorafenib—ABL1—Idarubicin—Doxorubicin—muscle cancer	0.00071	0.333	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Doxorubicin—muscle cancer	0.00071	0.333	CbGdCrCtD
Regorafenib—FLT1—smooth muscle tissue—muscle cancer	0.000691	0.00948	CbGeAlD
Regorafenib—TEK—renal system—muscle cancer	0.000688	0.00944	CbGeAlD
Regorafenib—EPHX2—vagina—muscle cancer	0.000687	0.00942	CbGeAlD
Regorafenib—RAF1—smooth muscle tissue—muscle cancer	0.000687	0.00942	CbGeAlD
Regorafenib—Hyperuricaemia—Vincristine—muscle cancer	0.000674	0.0141	CcSEcCtD
Regorafenib—FLT1—renal system—muscle cancer	0.000665	0.00912	CbGeAlD
Regorafenib—RAF1—renal system—muscle cancer	0.000661	0.00907	CbGeAlD
Regorafenib—FGFR1—tendon—muscle cancer	0.000659	0.00904	CbGeAlD
Regorafenib—KIT—embryo—muscle cancer	0.000658	0.00903	CbGeAlD
Regorafenib—Hepatotoxicity—Etoposide—muscle cancer	0.000656	0.0137	CcSEcCtD
Regorafenib—PDGFRA—smooth muscle tissue—muscle cancer	0.000647	0.00888	CbGeAlD
Regorafenib—FLT4—bone marrow—muscle cancer	0.000647	0.00887	CbGeAlD
Regorafenib—PDGFRB—embryo—muscle cancer	0.000643	0.00882	CbGeAlD
Regorafenib—BRAF—testis—muscle cancer	0.000641	0.0088	CbGeAlD
Regorafenib—Blood uric acid increased—Vincristine—muscle cancer	0.000637	0.0133	CcSEcCtD
Regorafenib—EPHA2—cardiac atrium—muscle cancer	0.000631	0.00866	CbGeAlD
Regorafenib—PDGFRA—renal system—muscle cancer	0.000623	0.00855	CbGeAlD
Regorafenib—TEK—cardiac atrium—muscle cancer	0.000616	0.00845	CbGeAlD
Regorafenib—EPHX2—testis—muscle cancer	0.000613	0.00841	CbGeAlD
Regorafenib—FGFR1—vagina—muscle cancer	0.000611	0.00838	CbGeAlD
Regorafenib—FLT1—cardiac atrium—muscle cancer	0.000595	0.00817	CbGeAlD
Regorafenib—UGT1A1—renal system—muscle cancer	0.000594	0.00816	CbGeAlD
Regorafenib—RAF1—cardiac atrium—muscle cancer	0.000592	0.00812	CbGeAlD
Regorafenib—RET—tendon—muscle cancer	0.000589	0.00809	CbGeAlD
Regorafenib—KDR—smooth muscle tissue—muscle cancer	0.000584	0.00801	CbGeAlD
Regorafenib—ABL1—embryo—muscle cancer	0.000573	0.00786	CbGeAlD
Regorafenib—FLT4—head—muscle cancer	0.000572	0.00785	CbGeAlD
Regorafenib—KDR—renal system—muscle cancer	0.000562	0.00771	CbGeAlD
Regorafenib—FLT4—testis—muscle cancer	0.000553	0.00758	CbGeAlD
Regorafenib—EPHA2—tendon—muscle cancer	0.00055	0.00755	CbGeAlD
Regorafenib—Mucosal inflammation—Methotrexate—muscle cancer	0.000548	0.0114	CcSEcCtD
Regorafenib—Hyperuricaemia—Etoposide—muscle cancer	0.000546	0.0114	CcSEcCtD
Regorafenib—FGFR1—testis—muscle cancer	0.000545	0.00748	CbGeAlD
Regorafenib—TEK—tendon—muscle cancer	0.000537	0.00737	CbGeAlD
Regorafenib—FLT1—tendon—muscle cancer	0.000519	0.00712	CbGeAlD
Regorafenib—KIT—smooth muscle tissue—muscle cancer	0.000517	0.0071	CbGeAlD
Regorafenib—RAF1—tendon—muscle cancer	0.000516	0.00708	CbGeAlD
Regorafenib—Blood uric acid increased—Etoposide—muscle cancer	0.000516	0.0108	CcSEcCtD
Regorafenib—Lymphopenia—Doxorubicin—muscle cancer	0.000514	0.0107	CcSEcCtD
Regorafenib—EPHA2—vagina—muscle cancer	0.000511	0.00701	CbGeAlD
Regorafenib—PDGFRB—smooth muscle tissue—muscle cancer	0.000505	0.00693	CbGeAlD
Regorafenib—RET—head—muscle cancer	0.000505	0.00693	CbGeAlD
Regorafenib—KDR—cardiac atrium—muscle cancer	0.000503	0.00691	CbGeAlD
Regorafenib—RAF1—bone marrow—muscle cancer	0.0005	0.00686	CbGeAlD
Regorafenib—Polyp—Methotrexate—muscle cancer	0.000499	0.0104	CcSEcCtD
Regorafenib—KIT—renal system—muscle cancer	0.000498	0.00683	CbGeAlD
Regorafenib—RET—testis—muscle cancer	0.000488	0.0067	CbGeAlD
Regorafenib—PDGFRB—renal system—muscle cancer	0.000486	0.00668	CbGeAlD
Regorafenib—PDGFRA—tendon—muscle cancer	0.000486	0.00667	CbGeAlD
Regorafenib—FLT1—vagina—muscle cancer	0.000482	0.00661	CbGeAlD
Regorafenib—FGFR2—head—muscle cancer	0.00048	0.00659	CbGeAlD
Regorafenib—RAF1—vagina—muscle cancer	0.000479	0.00657	CbGeAlD
Regorafenib—Mucosal inflammation—Doxorubicin—muscle cancer	0.000475	0.0099	CcSEcCtD
Regorafenib—EPHA2—head—muscle cancer	0.000472	0.00647	CbGeAlD
Regorafenib—Nail disorder—Methotrexate—muscle cancer	0.000468	0.00976	CcSEcCtD
Regorafenib—FGFR2—testis—muscle cancer	0.000464	0.00636	CbGeAlD
Regorafenib—TEK—head—muscle cancer	0.00046	0.00631	CbGeAlD
Regorafenib—Toxic epidermal necrolysis—Dactinomycin—muscle cancer	0.000458	0.00955	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Dactinomycin—muscle cancer	0.000458	0.00955	CcSEcCtD
Regorafenib—Hyponatraemia—Vincristine—muscle cancer	0.000456	0.00951	CcSEcCtD
Regorafenib—EPHA2—testis—muscle cancer	0.000456	0.00625	CbGeAlD
Regorafenib—Cyst—Methotrexate—muscle cancer	0.000454	0.00947	CcSEcCtD
Regorafenib—Hypophosphataemia—Doxorubicin—muscle cancer	0.000452	0.00943	CcSEcCtD
Regorafenib—PDGFRA—vagina—muscle cancer	0.000451	0.00619	CbGeAlD
Regorafenib—ABL1—smooth muscle tissue—muscle cancer	0.00045	0.00618	CbGeAlD
Regorafenib—FLT1—head—muscle cancer	0.000445	0.0061	CbGeAlD
Regorafenib—TEK—testis—muscle cancer	0.000444	0.0061	CbGeAlD
Regorafenib—RAF1—head—muscle cancer	0.000442	0.00607	CbGeAlD
Regorafenib—KDR—tendon—muscle cancer	0.000439	0.00602	CbGeAlD
Regorafenib—PDGFRB—cardiac atrium—muscle cancer	0.000436	0.00598	CbGeAlD
Regorafenib—ABL1—renal system—muscle cancer	0.000434	0.00595	CbGeAlD
Regorafenib—Polyp—Doxorubicin—muscle cancer	0.000432	0.00901	CcSEcCtD
Regorafenib—FLT1—testis—muscle cancer	0.00043	0.0059	CbGeAlD
Regorafenib—RAF1—testis—muscle cancer	0.000427	0.00586	CbGeAlD
Regorafenib—KDR—bone marrow—muscle cancer	0.000425	0.00583	CbGeAlD
Regorafenib—PDGFRA—head—muscle cancer	0.000417	0.00572	CbGeAlD
Regorafenib—Hypomagnesaemia—Doxorubicin—muscle cancer	0.000414	0.00863	CcSEcCtD
Regorafenib—Neutropenia—Dactinomycin—muscle cancer	0.000411	0.00857	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Vincristine—muscle cancer	0.000409	0.00853	CcSEcCtD
Regorafenib—KDR—vagina—muscle cancer	0.000407	0.00559	CbGeAlD
Regorafenib—Nail disorder—Doxorubicin—muscle cancer	0.000405	0.00845	CcSEcCtD
Regorafenib—PDGFRA—testis—muscle cancer	0.000403	0.00553	CbGeAlD
Regorafenib—Cyst—Doxorubicin—muscle cancer	0.000393	0.0082	CcSEcCtD
Regorafenib—Hepatotoxicity—Methotrexate—muscle cancer	0.000393	0.0082	CcSEcCtD
Regorafenib—ABL1—cardiac atrium—muscle cancer	0.000388	0.00533	CbGeAlD
Regorafenib—Stevens-Johnson syndrome—Dactinomycin—muscle cancer	0.000388	0.0081	CcSEcCtD
Regorafenib—Stomatitis—Dactinomycin—muscle cancer	0.000382	0.00796	CcSEcCtD
Regorafenib—PDGFRB—tendon—muscle cancer	0.00038	0.00521	CbGeAlD
Regorafenib—KIT—bone marrow—muscle cancer	0.000377	0.00517	CbGeAlD
Regorafenib—KDR—head—muscle cancer	0.000376	0.00516	CbGeAlD
Regorafenib—PDGFRB—bone marrow—muscle cancer	0.000368	0.00505	CbGeAlD
Regorafenib—Neutropenia—Vincristine—muscle cancer	0.000367	0.00766	CcSEcCtD
Regorafenib—KDR—testis—muscle cancer	0.000363	0.00498	CbGeAlD
Regorafenib—KIT—vagina—muscle cancer	0.000361	0.00495	CbGeAlD
Regorafenib—Weight decreased—Vincristine—muscle cancer	0.000355	0.00741	CcSEcCtD
Regorafenib—PDGFRB—vagina—muscle cancer	0.000352	0.00484	CbGeAlD
Regorafenib—Proteinuria—Methotrexate—muscle cancer	0.000345	0.00721	CcSEcCtD
Regorafenib—Acute coronary syndrome—Vincristine—muscle cancer	0.000345	0.0072	CcSEcCtD
Regorafenib—Myocardial infarction—Vincristine—muscle cancer	0.000343	0.00716	CcSEcCtD
Regorafenib—Stomatitis—Vincristine—muscle cancer	0.000341	0.00712	CcSEcCtD
Regorafenib—Protein urine present—Methotrexate—muscle cancer	0.000341	0.00711	CcSEcCtD
Regorafenib—ABL1—tendon—muscle cancer	0.000338	0.00464	CbGeAlD
Regorafenib—Musculoskeletal stiffness—Methotrexate—muscle cancer	0.000338	0.00706	CcSEcCtD
Regorafenib—Hyperbilirubinaemia—Methotrexate—muscle cancer	0.000334	0.00696	CcSEcCtD
Regorafenib—KIT—head—muscle cancer	0.000333	0.00457	CbGeAlD
Regorafenib—Erythema multiforme—Dactinomycin—muscle cancer	0.000332	0.00693	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Etoposide—muscle cancer	0.000331	0.00691	CcSEcCtD
Regorafenib—ABL1—bone marrow—muscle cancer	0.000328	0.0045	CbGeAlD
Regorafenib—Hyperuricaemia—Methotrexate—muscle cancer	0.000327	0.00683	CcSEcCtD
Regorafenib—PDGFRB—head—muscle cancer	0.000325	0.00447	CbGeAlD
Regorafenib—Alanine aminotransferase increased—Etoposide—muscle cancer	0.000324	0.00677	CcSEcCtD
Regorafenib—KIT—testis—muscle cancer	0.000322	0.00442	CbGeAlD
Regorafenib—Dysphonia—Doxorubicin—muscle cancer	0.000319	0.00666	CcSEcCtD
Regorafenib—PDGFRB—testis—muscle cancer	0.000314	0.00431	CbGeAlD
Regorafenib—ABL1—vagina—muscle cancer	0.000314	0.00431	CbGeAlD
Regorafenib—Liver injury—Doxorubicin—muscle cancer	0.000312	0.00652	CcSEcCtD
Regorafenib—Alopecia—Dactinomycin—muscle cancer	0.000311	0.00648	CcSEcCtD
Regorafenib—Urinary tract disorder—Vincristine—muscle cancer	0.00031	0.00647	CcSEcCtD
Regorafenib—Blood uric acid increased—Methotrexate—muscle cancer	0.000309	0.00645	CcSEcCtD
Regorafenib—Connective tissue disorder—Vincristine—muscle cancer	0.000309	0.00644	CcSEcCtD
Regorafenib—Urethral disorder—Vincristine—muscle cancer	0.000308	0.00642	CcSEcCtD
Regorafenib—Neutropenia—Etoposide—muscle cancer	0.000297	0.0062	CcSEcCtD
Regorafenib—Cardiac disorder—Vincristine—muscle cancer	0.000292	0.00608	CcSEcCtD
Regorafenib—ABL1—head—muscle cancer	0.00029	0.00398	CbGeAlD
Regorafenib—Hyperbilirubinaemia—Doxorubicin—muscle cancer	0.000289	0.00603	CcSEcCtD
Regorafenib—Hypocalcaemia—Doxorubicin—muscle cancer	0.000287	0.00599	CcSEcCtD
Regorafenib—Angiopathy—Vincristine—muscle cancer	0.000285	0.00595	CcSEcCtD
Regorafenib—Infestation—Etoposide—muscle cancer	0.000283	0.00591	CcSEcCtD
Regorafenib—Infestation NOS—Etoposide—muscle cancer	0.000283	0.00591	CcSEcCtD
Regorafenib—Hyperuricaemia—Doxorubicin—muscle cancer	0.000283	0.00591	CcSEcCtD
Regorafenib—Mediastinal disorder—Vincristine—muscle cancer	0.000283	0.00591	CcSEcCtD
Regorafenib—Anaemia—Dactinomycin—muscle cancer	0.000283	0.0059	CcSEcCtD
Regorafenib—CYP2C8—renal system—muscle cancer	0.000281	0.00386	CbGeAlD
Regorafenib—Stevens-Johnson syndrome—Etoposide—muscle cancer	0.000281	0.00586	CcSEcCtD
Regorafenib—ABL1—testis—muscle cancer	0.00028	0.00385	CbGeAlD
Regorafenib—Acute coronary syndrome—Etoposide—muscle cancer	0.000279	0.00583	CcSEcCtD
Regorafenib—Myocardial infarction—Etoposide—muscle cancer	0.000278	0.0058	CcSEcCtD
Regorafenib—Alopecia—Vincristine—muscle cancer	0.000278	0.00579	CcSEcCtD
Regorafenib—Stomatitis—Etoposide—muscle cancer	0.000276	0.00576	CcSEcCtD
Regorafenib—Neoplasm—Methotrexate—muscle cancer	0.000274	0.00572	CcSEcCtD
Regorafenib—Leukopenia—Dactinomycin—muscle cancer	0.000274	0.00572	CcSEcCtD
Regorafenib—Hepatobiliary disease—Etoposide—muscle cancer	0.000268	0.00559	CcSEcCtD
Regorafenib—Blood uric acid increased—Doxorubicin—muscle cancer	0.000268	0.00558	CcSEcCtD
Regorafenib—Anaemia—Vincristine—muscle cancer	0.000253	0.00527	CcSEcCtD
Regorafenib—CYP2B6—renal system—muscle cancer	0.000252	0.00346	CbGeAlD
Regorafenib—Urinary tract disorder—Etoposide—muscle cancer	0.000251	0.00524	CcSEcCtD
Regorafenib—Urethral disorder—Etoposide—muscle cancer	0.000249	0.0052	CcSEcCtD
Regorafenib—Infection—Dactinomycin—muscle cancer	0.000248	0.00518	CcSEcCtD
Regorafenib—Leukopenia—Vincristine—muscle cancer	0.000245	0.00511	CcSEcCtD
Regorafenib—Thrombocytopenia—Dactinomycin—muscle cancer	0.000245	0.0051	CcSEcCtD
Regorafenib—Erythema multiforme—Etoposide—muscle cancer	0.000241	0.00502	CcSEcCtD
Regorafenib—Neoplasm—Doxorubicin—muscle cancer	0.000238	0.00496	CcSEcCtD
Regorafenib—Cardiac disorder—Etoposide—muscle cancer	0.000236	0.00493	CcSEcCtD
Regorafenib—Hypertension—Vincristine—muscle cancer	0.000236	0.00493	CcSEcCtD
Regorafenib—CYP2C19—vagina—muscle cancer	0.000233	0.0032	CbGeAlD
Regorafenib—Angiopathy—Etoposide—muscle cancer	0.000231	0.00482	CcSEcCtD
Regorafenib—Mediastinal disorder—Etoposide—muscle cancer	0.000229	0.00478	CcSEcCtD
Regorafenib—Alopecia—Etoposide—muscle cancer	0.000225	0.00469	CcSEcCtD
Regorafenib—Infection—Vincristine—muscle cancer	0.000222	0.00463	CcSEcCtD
Regorafenib—Nervous system disorder—Vincristine—muscle cancer	0.000219	0.00457	CcSEcCtD
Regorafenib—Thrombocytopenia—Vincristine—muscle cancer	0.000218	0.00456	CcSEcCtD
Regorafenib—Decreased appetite—Dactinomycin—muscle cancer	0.000217	0.00453	CcSEcCtD
Regorafenib—Fatigue—Dactinomycin—muscle cancer	0.000215	0.00449	CcSEcCtD
Regorafenib—Pain—Dactinomycin—muscle cancer	0.000214	0.00446	CcSEcCtD
Regorafenib—ABCG2—bone marrow—muscle cancer	0.000207	0.00284	CbGeAlD
Regorafenib—Anaemia—Etoposide—muscle cancer	0.000205	0.00427	CcSEcCtD
Regorafenib—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000204	0.00426	CcSEcCtD
Regorafenib—CYP2C8—vagina—muscle cancer	0.000204	0.0028	CbGeAlD
Regorafenib—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.000198	0.00414	CcSEcCtD
Regorafenib—Leukopenia—Etoposide—muscle cancer	0.000198	0.00414	CcSEcCtD
Regorafenib—ABCG2—vagina—muscle cancer	0.000198	0.00272	CbGeAlD
Regorafenib—Abdominal pain—Dactinomycin—muscle cancer	0.000197	0.00412	CcSEcCtD
Regorafenib—Body temperature increased—Dactinomycin—muscle cancer	0.000197	0.00412	CcSEcCtD
Regorafenib—Decreased appetite—Vincristine—muscle cancer	0.000194	0.00405	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Vincristine—muscle cancer	0.000193	0.00402	CcSEcCtD
Regorafenib—Fatigue—Vincristine—muscle cancer	0.000192	0.00401	CcSEcCtD
Regorafenib—Hyponatraemia—Doxorubicin—muscle cancer	0.000192	0.004	CcSEcCtD
Regorafenib—Hypertension—Etoposide—muscle cancer	0.000191	0.00399	CcSEcCtD
Regorafenib—Pain—Vincristine—muscle cancer	0.000191	0.00398	CcSEcCtD
Regorafenib—CYP3A4—renal system—muscle cancer	0.00019	0.00261	CbGeAlD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000187	0.00391	CcSEcCtD
Regorafenib—CYP2B6—vagina—muscle cancer	0.000183	0.00251	CbGeAlD
Regorafenib—Gastrointestinal pain—Vincristine—muscle cancer	0.000182	0.00381	CcSEcCtD
Regorafenib—CYP2C8—testis—muscle cancer	0.000182	0.00249	CbGeAlD
Regorafenib—Infection—Etoposide—muscle cancer	0.00018	0.00375	CcSEcCtD
Regorafenib—Asthenia—Dactinomycin—muscle cancer	0.000179	0.00374	CcSEcCtD
Regorafenib—ABCB1—embryo—muscle cancer	0.000178	0.00244	CbGeAlD
Regorafenib—Neutropenia—Methotrexate—muscle cancer	0.000178	0.00371	CcSEcCtD
Regorafenib—Thrombocytopenia—Etoposide—muscle cancer	0.000177	0.00369	CcSEcCtD
Regorafenib—ABCG2—testis—muscle cancer	0.000177	0.00243	CbGeAlD
Regorafenib—Body temperature increased—Vincristine—muscle cancer	0.000176	0.00368	CcSEcCtD
Regorafenib—Abdominal pain—Vincristine—muscle cancer	0.000176	0.00368	CcSEcCtD
Regorafenib—Skin disorder—Etoposide—muscle cancer	0.000176	0.00366	CcSEcCtD
Regorafenib—Dry skin—Doxorubicin—muscle cancer	0.000175	0.00365	CcSEcCtD
Regorafenib—Hypokalaemia—Doxorubicin—muscle cancer	0.000174	0.00362	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000172	0.00358	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000172	0.00358	CcSEcCtD
Regorafenib—Diarrhoea—Dactinomycin—muscle cancer	0.000171	0.00357	CcSEcCtD
Regorafenib—Infestation NOS—Methotrexate—muscle cancer	0.00017	0.00354	CcSEcCtD
Regorafenib—Infestation—Methotrexate—muscle cancer	0.00017	0.00354	CcSEcCtD
Regorafenib—CYP2B6—head—muscle cancer	0.000169	0.00232	CbGeAlD
Regorafenib—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000168	0.00351	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000168	0.00351	CcSEcCtD
Regorafenib—Stomatitis—Methotrexate—muscle cancer	0.000165	0.00345	CcSEcCtD
Regorafenib—CYP2B6—testis—muscle cancer	0.000163	0.00224	CbGeAlD
Regorafenib—Hepatobiliary disease—Methotrexate—muscle cancer	0.000161	0.00335	CcSEcCtD
Regorafenib—Asthenia—Vincristine—muscle cancer	0.00016	0.00334	CcSEcCtD
Regorafenib—Vomiting—Dactinomycin—muscle cancer	0.000159	0.00331	CcSEcCtD
Regorafenib—Rash—Dactinomycin—muscle cancer	0.000157	0.00329	CcSEcCtD
Regorafenib—Decreased appetite—Etoposide—muscle cancer	0.000157	0.00328	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Etoposide—muscle cancer	0.000156	0.00326	CcSEcCtD
Regorafenib—Fatigue—Etoposide—muscle cancer	0.000156	0.00325	CcSEcCtD
Regorafenib—Pain—Etoposide—muscle cancer	0.000155	0.00323	CcSEcCtD
Regorafenib—Neutropenia—Doxorubicin—muscle cancer	0.000154	0.00322	CcSEcCtD
Regorafenib—Haemoglobin—Methotrexate—muscle cancer	0.000153	0.0032	CcSEcCtD
Regorafenib—Diarrhoea—Vincristine—muscle cancer	0.000153	0.00319	CcSEcCtD
Regorafenib—Haemorrhage—Methotrexate—muscle cancer	0.000152	0.00318	CcSEcCtD
Regorafenib—Urinary tract disorder—Methotrexate—muscle cancer	0.000151	0.00314	CcSEcCtD
Regorafenib—Urethral disorder—Methotrexate—muscle cancer	0.000149	0.00312	CcSEcCtD
Regorafenib—Weight decreased—Doxorubicin—muscle cancer	0.000149	0.00311	CcSEcCtD
Regorafenib—Nausea—Dactinomycin—muscle cancer	0.000148	0.0031	CcSEcCtD
Regorafenib—Gastrointestinal pain—Etoposide—muscle cancer	0.000148	0.00308	CcSEcCtD
Regorafenib—Infestation—Doxorubicin—muscle cancer	0.000147	0.00307	CcSEcCtD
Regorafenib—Infestation NOS—Doxorubicin—muscle cancer	0.000147	0.00307	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000146	0.00304	CcSEcCtD
Regorafenib—Erythema multiforme—Methotrexate—muscle cancer	0.000144	0.00301	CcSEcCtD
Regorafenib—Stomatitis—Doxorubicin—muscle cancer	0.000143	0.00299	CcSEcCtD
Regorafenib—Abdominal pain—Etoposide—muscle cancer	0.000143	0.00298	CcSEcCtD
Regorafenib—Body temperature increased—Etoposide—muscle cancer	0.000143	0.00298	CcSEcCtD
Regorafenib—Vomiting—Vincristine—muscle cancer	0.000142	0.00296	CcSEcCtD
Regorafenib—Cardiac disorder—Methotrexate—muscle cancer	0.000141	0.00295	CcSEcCtD
Regorafenib—Rash—Vincristine—muscle cancer	0.000141	0.00294	CcSEcCtD
Regorafenib—Dermatitis—Vincristine—muscle cancer	0.000141	0.00293	CcSEcCtD
Regorafenib—Headache—Vincristine—muscle cancer	0.00014	0.00292	CcSEcCtD
Regorafenib—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000139	0.0029	CcSEcCtD
Regorafenib—Angiopathy—Methotrexate—muscle cancer	0.000138	0.00288	CcSEcCtD
Regorafenib—Mediastinal disorder—Methotrexate—muscle cancer	0.000137	0.00287	CcSEcCtD
Regorafenib—ABCB1—renal system—muscle cancer	0.000135	0.00185	CbGeAlD
Regorafenib—Alopecia—Methotrexate—muscle cancer	0.000135	0.00281	CcSEcCtD
Regorafenib—Malnutrition—Methotrexate—muscle cancer	0.000133	0.00277	CcSEcCtD
Regorafenib—Haemoglobin—Doxorubicin—muscle cancer	0.000133	0.00277	CcSEcCtD
Regorafenib—Nausea—Vincristine—muscle cancer	0.000133	0.00277	CcSEcCtD
Regorafenib—Haemorrhage—Doxorubicin—muscle cancer	0.000132	0.00275	CcSEcCtD
Regorafenib—Urinary tract disorder—Doxorubicin—muscle cancer	0.00013	0.00272	CcSEcCtD
Regorafenib—Asthenia—Etoposide—muscle cancer	0.00013	0.00271	CcSEcCtD
Regorafenib—Connective tissue disorder—Doxorubicin—muscle cancer	0.00013	0.00271	CcSEcCtD
Regorafenib—Urethral disorder—Doxorubicin—muscle cancer	0.000129	0.0027	CcSEcCtD
Regorafenib—Erythema multiforme—Doxorubicin—muscle cancer	0.000125	0.0026	CcSEcCtD
Regorafenib—Diarrhoea—Etoposide—muscle cancer	0.000124	0.00258	CcSEcCtD
Regorafenib—Anaemia—Methotrexate—muscle cancer	0.000123	0.00256	CcSEcCtD
Regorafenib—Cardiac disorder—Doxorubicin—muscle cancer	0.000122	0.00256	CcSEcCtD
Regorafenib—Angiopathy—Doxorubicin—muscle cancer	0.00012	0.0025	CcSEcCtD
Regorafenib—Mediastinal disorder—Doxorubicin—muscle cancer	0.000119	0.00248	CcSEcCtD
Regorafenib—Leukopenia—Methotrexate—muscle cancer	0.000119	0.00248	CcSEcCtD
Regorafenib—Alopecia—Doxorubicin—muscle cancer	0.000117	0.00243	CcSEcCtD
Regorafenib—Vomiting—Etoposide—muscle cancer	0.000115	0.0024	CcSEcCtD
Regorafenib—Malnutrition—Doxorubicin—muscle cancer	0.000115	0.0024	CcSEcCtD
Regorafenib—Rash—Etoposide—muscle cancer	0.000114	0.00238	CcSEcCtD
Regorafenib—Dermatitis—Etoposide—muscle cancer	0.000114	0.00238	CcSEcCtD
Regorafenib—Headache—Etoposide—muscle cancer	0.000113	0.00236	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000112	0.00234	CcSEcCtD
Regorafenib—Infection—Methotrexate—muscle cancer	0.000108	0.00224	CcSEcCtD
Regorafenib—Nausea—Etoposide—muscle cancer	0.000107	0.00224	CcSEcCtD
Regorafenib—Nervous system disorder—Methotrexate—muscle cancer	0.000106	0.00222	CcSEcCtD
Regorafenib—Anaemia—Doxorubicin—muscle cancer	0.000106	0.00222	CcSEcCtD
Regorafenib—Thrombocytopenia—Methotrexate—muscle cancer	0.000106	0.00221	CcSEcCtD
Regorafenib—Skin disorder—Methotrexate—muscle cancer	0.000105	0.00219	CcSEcCtD
Regorafenib—Leukopenia—Doxorubicin—muscle cancer	0.000103	0.00215	CcSEcCtD
Regorafenib—ABCB1—bone marrow—muscle cancer	0.000102	0.0014	CbGeAlD
Regorafenib—Hypertension—Doxorubicin—muscle cancer	9.92e-05	0.00207	CcSEcCtD
Regorafenib—ABCB1—vagina—muscle cancer	9.77e-05	0.00134	CbGeAlD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	9.71e-05	0.00203	CcSEcCtD
Regorafenib—Dry mouth—Doxorubicin—muscle cancer	9.57e-05	0.002	CcSEcCtD
Regorafenib—Decreased appetite—Methotrexate—muscle cancer	9.41e-05	0.00196	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Methotrexate—muscle cancer	9.35e-05	0.00195	CcSEcCtD
Regorafenib—Fatigue—Methotrexate—muscle cancer	9.34e-05	0.00195	CcSEcCtD
Regorafenib—Infection—Doxorubicin—muscle cancer	9.31e-05	0.00194	CcSEcCtD
Regorafenib—Pain—Methotrexate—muscle cancer	9.26e-05	0.00193	CcSEcCtD
Regorafenib—Nervous system disorder—Doxorubicin—muscle cancer	9.19e-05	0.00192	CcSEcCtD
Regorafenib—Thrombocytopenia—Doxorubicin—muscle cancer	9.18e-05	0.00192	CcSEcCtD
Regorafenib—Skin disorder—Doxorubicin—muscle cancer	9.11e-05	0.0019	CcSEcCtD
Regorafenib—ABCB1—head—muscle cancer	9.02e-05	0.00124	CbGeAlD
Regorafenib—Gastrointestinal pain—Methotrexate—muscle cancer	8.85e-05	0.00185	CcSEcCtD
Regorafenib—ABCB1—testis—muscle cancer	8.71e-05	0.0012	CbGeAlD
Regorafenib—Abdominal pain—Methotrexate—muscle cancer	8.56e-05	0.00179	CcSEcCtD
Regorafenib—Body temperature increased—Methotrexate—muscle cancer	8.56e-05	0.00179	CcSEcCtD
Regorafenib—Decreased appetite—Doxorubicin—muscle cancer	8.15e-05	0.0017	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Doxorubicin—muscle cancer	8.09e-05	0.00169	CcSEcCtD
Regorafenib—Fatigue—Doxorubicin—muscle cancer	8.08e-05	0.00169	CcSEcCtD
Regorafenib—Pain—Doxorubicin—muscle cancer	8.02e-05	0.00167	CcSEcCtD
Regorafenib—Asthenia—Methotrexate—muscle cancer	7.77e-05	0.00162	CcSEcCtD
Regorafenib—Gastrointestinal pain—Doxorubicin—muscle cancer	7.67e-05	0.0016	CcSEcCtD
Regorafenib—Abdominal pain—Doxorubicin—muscle cancer	7.41e-05	0.00155	CcSEcCtD
Regorafenib—Body temperature increased—Doxorubicin—muscle cancer	7.41e-05	0.00155	CcSEcCtD
Regorafenib—Diarrhoea—Methotrexate—muscle cancer	7.41e-05	0.00155	CcSEcCtD
Regorafenib—Vomiting—Methotrexate—muscle cancer	6.88e-05	0.00144	CcSEcCtD
Regorafenib—Rash—Methotrexate—muscle cancer	6.83e-05	0.00142	CcSEcCtD
Regorafenib—Dermatitis—Methotrexate—muscle cancer	6.82e-05	0.00142	CcSEcCtD
Regorafenib—Headache—Methotrexate—muscle cancer	6.78e-05	0.00142	CcSEcCtD
Regorafenib—Asthenia—Doxorubicin—muscle cancer	6.73e-05	0.0014	CcSEcCtD
Regorafenib—Nausea—Methotrexate—muscle cancer	6.43e-05	0.00134	CcSEcCtD
Regorafenib—Diarrhoea—Doxorubicin—muscle cancer	6.42e-05	0.00134	CcSEcCtD
Regorafenib—Vomiting—Doxorubicin—muscle cancer	5.96e-05	0.00124	CcSEcCtD
Regorafenib—Rash—Doxorubicin—muscle cancer	5.91e-05	0.00123	CcSEcCtD
Regorafenib—Dermatitis—Doxorubicin—muscle cancer	5.91e-05	0.00123	CcSEcCtD
Regorafenib—Headache—Doxorubicin—muscle cancer	5.87e-05	0.00123	CcSEcCtD
Regorafenib—Nausea—Doxorubicin—muscle cancer	5.57e-05	0.00116	CcSEcCtD
Regorafenib—PDGFRB—Disease—ENO2—muscle cancer	2.14e-05	0.000158	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—FOXO1—muscle cancer	2.13e-05	0.000157	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.13e-05	0.000157	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—FOXO4—muscle cancer	2.1e-05	0.000155	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—FOXO4—muscle cancer	2.09e-05	0.000155	CbGpPWpGaD
Regorafenib—RAF1—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	2.09e-05	0.000155	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—KIT—muscle cancer	2.09e-05	0.000154	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—KIT—muscle cancer	2.09e-05	0.000154	CbGpPWpGaD
Regorafenib—FGFR2—Disease—FOXO4—muscle cancer	2.08e-05	0.000154	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—FOXO1—muscle cancer	2.05e-05	0.000151	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—FOXO1—muscle cancer	2.05e-05	0.000151	CbGpPWpGaD
Regorafenib—KIT—Disease—FOXO4—muscle cancer	2.04e-05	0.000151	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—KIT—muscle cancer	2.03e-05	0.00015	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—KIT—muscle cancer	2.02e-05	0.000149	CbGpPWpGaD
Regorafenib—MAPK11—Cellular responses to stress—TP53—muscle cancer	2e-05	0.000148	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—FH—muscle cancer	1.98e-05	0.000146	CbGpPWpGaD
Regorafenib—RAF1—MAPK Signaling Pathway—TP53—muscle cancer	1.97e-05	0.000145	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—FOXO4—muscle cancer	1.95e-05	0.000144	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—KIT—muscle cancer	1.95e-05	0.000144	CbGpPWpGaD
Regorafenib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.94e-05	0.000144	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—KIT—muscle cancer	1.94e-05	0.000143	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—HMGA1—muscle cancer	1.94e-05	0.000143	CbGpPWpGaD
Regorafenib—FGFR1—Disease—FOXO4—muscle cancer	1.94e-05	0.000143	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—FOXO4—muscle cancer	1.93e-05	0.000143	CbGpPWpGaD
Regorafenib—EPHX2—Metabolism—PTGS2—muscle cancer	1.93e-05	0.000143	CbGpPWpGaD
Regorafenib—FGFR1—Axon guidance—VEGFA—muscle cancer	1.92e-05	0.000142	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CNR1—muscle cancer	1.92e-05	0.000142	CbGpPWpGaD
Regorafenib—RAF1—Disease—ENO2—muscle cancer	1.9e-05	0.000141	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.9e-05	0.00014	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—FOXO4—muscle cancer	1.89e-05	0.000139	CbGpPWpGaD
Regorafenib—MAPK11—Innate Immune System—MDM2—muscle cancer	1.87e-05	0.000138	CbGpPWpGaD
Regorafenib—KDR—Developmental Biology—VEGFA—muscle cancer	1.87e-05	0.000138	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—FOXO4—muscle cancer	1.84e-05	0.000136	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—PTCH1—muscle cancer	1.84e-05	0.000136	CbGpPWpGaD
Regorafenib—ABL1—Immune System—FOXO4—muscle cancer	1.84e-05	0.000136	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—PTCH1—muscle cancer	1.83e-05	0.000135	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—KIT—muscle cancer	1.82e-05	0.000135	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—FOXO1—muscle cancer	1.81e-05	0.000134	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CNR1—muscle cancer	1.81e-05	0.000134	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—CNR1—muscle cancer	1.81e-05	0.000133	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—MED12—muscle cancer	1.8e-05	0.000133	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—MED12—muscle cancer	1.8e-05	0.000133	CbGpPWpGaD
Regorafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.78e-05	0.000131	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—KIT—muscle cancer	1.78e-05	0.000131	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—KIT—muscle cancer	1.75e-05	0.000129	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—FOXO4—muscle cancer	1.74e-05	0.000129	CbGpPWpGaD
Regorafenib—RAF1—Disease—HMGA1—muscle cancer	1.73e-05	0.000128	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.73e-05	0.000128	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—MDM2—muscle cancer	1.71e-05	0.000127	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—PTCH1—muscle cancer	1.69e-05	0.000125	CbGpPWpGaD
Regorafenib—ABL1—Axon guidance—VEGFA—muscle cancer	1.69e-05	0.000124	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—MDM2—muscle cancer	1.68e-05	0.000124	CbGpPWpGaD
Regorafenib—RAF1—Immune System—FOXO4—muscle cancer	1.68e-05	0.000124	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—FH—muscle cancer	1.68e-05	0.000124	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—FOXO1—muscle cancer	1.66e-05	0.000123	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—PTCH1—muscle cancer	1.66e-05	0.000123	CbGpPWpGaD
Regorafenib—BRAF—Disease—FOXO1—muscle cancer	1.66e-05	0.000122	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—MDM2—muscle cancer	1.65e-05	0.000122	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—MDM2—muscle cancer	1.65e-05	0.000122	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—ENO2—muscle cancer	1.64e-05	0.000121	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—ENO2—muscle cancer	1.64e-05	0.000121	CbGpPWpGaD
Regorafenib—KIT—Immune System—FOXO1—muscle cancer	1.63e-05	0.000121	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—KIT—muscle cancer	1.62e-05	0.00012	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—MDM2—muscle cancer	1.62e-05	0.000119	CbGpPWpGaD
Regorafenib—MAPK11—Developmental Biology—VEGFA—muscle cancer	1.61e-05	0.000119	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—MDM2—muscle cancer	1.6e-05	0.000118	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—MDM2—muscle cancer	1.59e-05	0.000118	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—FOXO4—muscle cancer	1.59e-05	0.000117	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—PTCH1—muscle cancer	1.58e-05	0.000117	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—PTCH1—muscle cancer	1.57e-05	0.000116	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—FOXO4—muscle cancer	1.57e-05	0.000116	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IGF2—muscle cancer	1.57e-05	0.000116	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—KIT—muscle cancer	1.56e-05	0.000115	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—KIT—muscle cancer	1.56e-05	0.000115	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CNR1—muscle cancer	1.56e-05	0.000115	CbGpPWpGaD
Regorafenib—RAF1—Disease—FOXO4—muscle cancer	1.55e-05	0.000115	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—FOXO1—muscle cancer	1.55e-05	0.000115	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—FOXO1—muscle cancer	1.55e-05	0.000114	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CNR1—muscle cancer	1.54e-05	0.000114	CbGpPWpGaD
Regorafenib—RAF1—Axon guidance—VEGFA—muscle cancer	1.54e-05	0.000114	CbGpPWpGaD
Regorafenib—FGFR2—Disease—FOXO1—muscle cancer	1.54e-05	0.000113	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—MDM2—muscle cancer	1.53e-05	0.000113	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—MDM2—muscle cancer	1.53e-05	0.000113	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—MED12—muscle cancer	1.53e-05	0.000113	CbGpPWpGaD
Regorafenib—KIT—Disease—FOXO1—muscle cancer	1.51e-05	0.000111	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—FH—muscle cancer	1.5e-05	0.00011	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IGF2—muscle cancer	1.48e-05	0.000109	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	1.46e-05	0.000108	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—FH—muscle cancer	1.46e-05	0.000108	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—FOXO4—muscle cancer	1.46e-05	0.000108	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—FOXO1—muscle cancer	1.44e-05	0.000106	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—MDM2—muscle cancer	1.44e-05	0.000106	CbGpPWpGaD
Regorafenib—FGFR1—Disease—FOXO1—muscle cancer	1.43e-05	0.000106	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—FOXO4—muscle cancer	1.43e-05	0.000106	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CNR1—muscle cancer	1.43e-05	0.000106	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—FOXO1—muscle cancer	1.43e-05	0.000105	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PTCH1—muscle cancer	1.42e-05	0.000105	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	1.41e-05	0.000104	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CNR1—muscle cancer	1.4e-05	0.000104	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—MDM2—muscle cancer	1.4e-05	0.000103	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—FOXO1—muscle cancer	1.39e-05	0.000103	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—ENO2—muscle cancer	1.39e-05	0.000103	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—KIT—muscle cancer	1.38e-05	0.000102	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—MDM2—muscle cancer	1.38e-05	0.000102	CbGpPWpGaD
Regorafenib—FGFR1—Developmental Biology—VEGFA—muscle cancer	1.37e-05	0.000101	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—FH—muscle cancer	1.36e-05	0.000101	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—FOXO1—muscle cancer	1.36e-05	0.000101	CbGpPWpGaD
Regorafenib—ABL1—Immune System—FOXO1—muscle cancer	1.36e-05	0.0001	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—FOXO4—muscle cancer	1.36e-05	0.0001	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—FOXO4—muscle cancer	1.35e-05	0.0001	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CNR1—muscle cancer	1.33e-05	9.84e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CNR1—muscle cancer	1.33e-05	9.81e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—FOXO1—muscle cancer	1.29e-05	9.5e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.28e-05	9.47e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—MDM2—muscle cancer	1.28e-05	9.45e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IGF2—muscle cancer	1.27e-05	9.4e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—KIT—muscle cancer	1.27e-05	9.36e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PTCH1—muscle cancer	1.26e-05	9.34e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—KIT—muscle cancer	1.26e-05	9.33e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IGF2—muscle cancer	1.26e-05	9.31e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—VEGFA—muscle cancer	1.25e-05	9.24e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—FOXO1—muscle cancer	1.24e-05	9.17e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—MDM2—muscle cancer	1.23e-05	9.07e-05	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—MDM2—muscle cancer	1.23e-05	9.07e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—FOXO4—muscle cancer	1.22e-05	9.01e-05	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—VEGFA—muscle cancer	1.2e-05	8.88e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CNR1—muscle cancer	1.2e-05	8.84e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—KIT—muscle cancer	1.18e-05	8.73e-05	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—VEGFA—muscle cancer	1.18e-05	8.71e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—KIT—muscle cancer	1.18e-05	8.7e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—FOXO1—muscle cancer	1.17e-05	8.65e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—KIT—muscle cancer	1.17e-05	8.64e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IGF2—muscle cancer	1.17e-05	8.63e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—FOXO1—muscle cancer	1.16e-05	8.57e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IGF2—muscle cancer	1.15e-05	8.48e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—FOXO1—muscle cancer	1.15e-05	8.47e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—MED12—muscle cancer	1.12e-05	8.26e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.11e-05	8.19e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—VEGFA—muscle cancer	1.1e-05	8.13e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—KIT—muscle cancer	1.1e-05	8.11e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—KIT—muscle cancer	1.09e-05	8.06e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IGF2—muscle cancer	1.09e-05	8.05e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—KIT—muscle cancer	1.09e-05	8.04e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—MDM2—muscle cancer	1.09e-05	8.03e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—FOXO4—muscle cancer	1.09e-05	8.03e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IGF2—muscle cancer	1.09e-05	8.02e-05	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—VEGFA—muscle cancer	1.08e-05	7.97e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—FOXO1—muscle cancer	1.08e-05	7.94e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CNR1—muscle cancer	1.07e-05	7.88e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—KIT—muscle cancer	1.06e-05	7.84e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—FOXO1—muscle cancer	1.06e-05	7.8e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—KIT—muscle cancer	1.04e-05	7.67e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—KIT—muscle cancer	1.03e-05	7.64e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ENO2—muscle cancer	1.02e-05	7.53e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—FOXO1—muscle cancer	1e-05	7.4e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—FOXO1—muscle cancer	1e-05	7.38e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—MDM2—muscle cancer	9.98e-06	7.37e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—MDM2—muscle cancer	9.94e-06	7.34e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—MDM2—muscle cancer	9.8e-06	7.24e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—KIT—muscle cancer	9.8e-06	7.24e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IGF2—muscle cancer	9.79e-06	7.23e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—PTGS2—muscle cancer	9.59e-06	7.08e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—MED12—muscle cancer	9.47e-06	6.99e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—KIT—muscle cancer	9.46e-06	6.99e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—TP53—muscle cancer	9.45e-06	6.98e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—VEGFA—muscle cancer	9.33e-06	6.89e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—MDM2—muscle cancer	9.3e-06	6.87e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—MDM2—muscle cancer	9.28e-06	6.85e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—MDM2—muscle cancer	9.22e-06	6.81e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—MDM2—muscle cancer	9.05e-06	6.69e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—FOXO1—muscle cancer	9.01e-06	6.65e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—FH—muscle cancer	8.99e-06	6.64e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—KIT—muscle cancer	8.93e-06	6.59e-05	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—TP53—muscle cancer	8.92e-06	6.58e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—PTGS2—muscle cancer	8.88e-06	6.56e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—KIT—muscle cancer	8.84e-06	6.53e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—KIT—muscle cancer	8.74e-06	6.45e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—PTGS2—muscle cancer	8.73e-06	6.44e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IGF2—muscle cancer	8.72e-06	6.44e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—MDM2—muscle cancer	8.65e-06	6.39e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ENO2—muscle cancer	8.63e-06	6.38e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—MDM2—muscle cancer	8.59e-06	6.34e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—MDM2—muscle cancer	8.57e-06	6.33e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—MED12—muscle cancer	8.45e-06	6.24e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	8.38e-06	6.19e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—MDM2—muscle cancer	8.36e-06	6.18e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—PTGS2—muscle cancer	8.28e-06	6.12e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—PTGS2—muscle cancer	8.26e-06	6.1e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—MED12—muscle cancer	8.25e-06	6.09e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—KIT—muscle cancer	8.19e-06	6.05e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—MDM2—muscle cancer	8.17e-06	6.04e-05	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—TP53—muscle cancer	8.15e-06	6.02e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—MDM2—muscle cancer	8.15e-06	6.02e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—FOXO1—muscle cancer	8.03e-06	5.93e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—MDM2—muscle cancer	7.72e-06	5.7e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—MED12—muscle cancer	7.71e-06	5.69e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ENO2—muscle cancer	7.71e-06	5.69e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—KIT—muscle cancer	7.64e-06	5.64e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—KIT—muscle cancer	7.62e-06	5.63e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ENO2—muscle cancer	7.52e-06	5.55e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—MDM2—muscle cancer	7.45e-06	5.5e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—PTGS2—muscle cancer	7.44e-06	5.5e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—TP53—muscle cancer	7.05e-06	5.21e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MDM2—muscle cancer	7.03e-06	5.19e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ENO2—muscle cancer	7.03e-06	5.19e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MDM2—muscle cancer	6.96e-06	5.14e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—MDM2—muscle cancer	6.88e-06	5.08e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—KIT—muscle cancer	6.86e-06	5.07e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.75e-06	4.99e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—PTGS2—muscle cancer	6.63e-06	4.9e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—VEGFA—muscle cancer	6.57e-06	4.85e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MDM2—muscle cancer	6.45e-06	4.77e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MDM2—muscle cancer	6.34e-06	4.68e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—VEGFA—muscle cancer	6.21e-06	4.58e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—KIT—muscle cancer	6.12e-06	4.52e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.03e-06	4.45e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MDM2—muscle cancer	6.02e-06	4.44e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MDM2—muscle cancer	6e-06	4.43e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PTGS2—muscle cancer	5.71e-06	4.22e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PTGS2—muscle cancer	5.71e-06	4.22e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.49e-06	4.06e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MDM2—muscle cancer	5.41e-06	3.99e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—VEGFA—muscle cancer	5.34e-06	3.94e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—VEGFA—muscle cancer	5.29e-06	3.91e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—MED12—muscle cancer	5.08e-06	3.75e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TP53—muscle cancer	4.96e-06	3.67e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—VEGFA—muscle cancer	4.9e-06	3.62e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTGS2—muscle cancer	4.84e-06	3.58e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MDM2—muscle cancer	4.82e-06	3.56e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—VEGFA—muscle cancer	4.81e-06	3.56e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TP53—muscle cancer	4.69e-06	3.46e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ENO2—muscle cancer	4.63e-06	3.42e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—VEGFA—muscle cancer	4.57e-06	3.37e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—VEGFA—muscle cancer	4.56e-06	3.37e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—VEGFA—muscle cancer	4.1e-06	3.03e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—muscle cancer	4.03e-06	2.98e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—muscle cancer	4e-06	2.95e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—muscle cancer	3.7e-06	2.74e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—VEGFA—muscle cancer	3.66e-06	2.7e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—muscle cancer	3.64e-06	2.69e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTGS2—muscle cancer	3.55e-06	2.62e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—muscle cancer	3.45e-06	2.55e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—muscle cancer	3.44e-06	2.54e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—muscle cancer	3.1e-06	2.29e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTGS2—muscle cancer	3.01e-06	2.22e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—muscle cancer	2.76e-06	2.04e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTGS2—muscle cancer	2.68e-06	1.98e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTGS2—muscle cancer	2.62e-06	1.93e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTGS2—muscle cancer	2.45e-06	1.81e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTGS2—muscle cancer	1.61e-06	1.19e-05	CbGpPWpGaD
